For emergency use, Covaxin has been given the approval to be utilized in 13 countries from January 31st as per WHO. Giving complete details about Covaxin, the minister of state ( MoS ) for health, Bharati Pravin Pawar in Lok Sabha said that covaxin has been granted by EUL Or emergency use listing by the national regulator drug controller general of India for the age group of 12 to 18 years of age on 24th of December 2021.
She also mentioned that the covid-19 working group of the national technical advisory group on immunization has recommended the covid-19 vaccination in teenagers aged 15 to 18 years.
She further informed that this grant of approval for covaxin is a scientific and Technical process for which data needs to be submitted to the regulator by the manufacturer of the vaccine as per the prescribed rules.
Regarding the supplies, she also informs that there is no specific information which has been brought to notice by the other foreign companies that they are facing difficulties in the covaxin supply. During the second surge of covid-19 cases in april-may 2021 in India, the national covid-19 vaccination program requirements were prioritised.
This might have impacted the following commercial contracts which were entered by domestic vaccine manufacturers. The ministry of external affairs also informed that there has been no financial loss incurred ever since the second Surge of covid-19 pandemic in the country. However, the domestic vaccine has been produced in utilised by the national covid-19 vaccination program.